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interleukin-2 receptor expression
PHILIPPE ZA0uI, WAYNE GREEN, and RAYMOND M. HAKIM
Division of Nephrology, Department of Medicine, Vanderbilt University Medical Center, and Histocompatibility Laboratory, Veterans
Administration Medical Center, Nashville, Tennessee, USA
Hemodialysis with cuprophane membrane modulates interleukin-2
receptor expression. Chronic dialysis patients have several indices of
immune deficiency. We examined the hypothesis that the biocompati-
bility of dialysis membranes may influence the ability of lymphocytes to
express interleukin-2 (IL-2) receptors on their surface, a key event in
cellular immune response. We investigated the potential role of the
dialysis membrane in eight chronic hemodialysis patients. The study
design was a cross-over study using cuprophane and polyrnethyl-
methacrylate (PMMA) membranes. Chronic dialysis with new Cu-
prophane membrane leads to an increase in baseline expression of the
two subunits of IL-2 receptors, IL2Ra (p55, CD25) and IL-2R/3 (p7°), in
peripheral blood mononuclear cell (PBMC). However, Phytohemagglu-
tinin (PHA) stimulation of PBMC harvested after two weeks of dialysis
with cuprophane membrane showed a markedly decreased expression
of high affinity 1L-2 receptors. These findings are reversed when
patients were dialyzed with a PMMA membrane which is also associ-
ated with minimal complement activation. The increased expression of
IL-2 receptor subunits are reproduced in vitro by direct contact of
PBMC with cuprophane membrane and by the addition of the anaphy-
latoxin C5a. This study confirms the participation of lymphocytes in the
complex blood-membrane interactions that occurs during dialysis; the
results may be relevant to observations of immune deficiency in dialysis
patients.
Cuprophane hemodialysis membranes have been shown to
activate several pathways of the inflammatory response, as well
as cellular elements such as neutrophils, monocytes and plate-
lets [1—4]. These inflammatory responses are less evident with
non-cellulosic membranes such as the polymethylmethacrylate
(PMMA) or polyacrylonitrile (PAN) membrane [3].
Lymphocytes have been assumed to be passive bystanders in
this complex blood-membrane interaction, although minor
changes in lymphocyte count and subsets have been demon-
strated [1, 5, 6]. Recently however, specific markers of lym-
phocyte activation such as increased numbers of T-lymphocyte
bearing interleukin-2 receptors (TAC antigen) and increased
soluble interleukin-2 receptor levels have been demonstrated in
dialysis patients [7, 81.
IL-2 receptors (IL-2R) are complex and made up of at least
two subunits: a and /3 [9]. The IL-2Ra subunit (also known as
TAC antigen, p55 or CD25) is expressed de novo; its expression
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is an index of lymphocyte activation and the extent of activation
is expressed as the percent of circulating IL-2Ra positive cells
[10]. The /3-subunit (IL-2R/3) also known as p70 subunit is
expressed constitutively on resting T-cells and is regulated
separately [11]. However, increased expression of IL-2R13 is
also considered a hallmark of lymphocyte activation [11, 12].
These subunits have low affinity for IL-2, but their association
results in a smaller number of receptor complexes, IL-2R, with
high affinity for IL-2 (Kd — 10 pM) [13]. Several studies have
indicated that this high affinity receptor is uniquely involved in
the rapid binding and internalization of IL-2 and mediates most
of its biological activities [13—16]. Defects in the ability of
T-lymphocytes to express high-affinity IL-2 receptors are asso-
ciated with impaired lymphocyte responses in a number of
diseases [17—21].
Because of the importance of high-affinity IL-2 receptor
expression in immune responses, we hypothesized that defects
in cellular immunity seen in hemodialysis patients may be
related to defects in the ability of lymphocytes harvested from
these patients to express high-affinity IL-2 receptors. We there-
fore studied the potential role of the dialysis membrane on the
expression of these receptors in eight chronic hemodialysis
patients in a short term, prospective cross-over design using
either cuprophane or PMMA membranes for two weeks each.
In parallel, we also measured the precent of lymphocytes which
express the subunits of IL-2 receptors, IL-2Ra and IL-2R/3, as
indices of lymphocyte activation. The results indicate a proba-
ble role for dialysis membrane in the ability of lymphocytes to
express high-affinity IL-2 receptors and its subunits; these
findings may be relevant to observations of cellular immune
deficiency in dialysis patients.
Methods
Patients
Eight hemodialysis patients, on chronic hemodialysis for 44
24 months were selected for participation in this study. All
patients were previously dialyzed with reused cuprophane
membrane involving the use of formaldehyde in the reuse
process. This reuse procedure significantly attenuates the com-
plement activating ability of cuprophane membranes [3]. On
average, the number of reuses for each dialyzer was 12; thus,
prior to their participation in the protocol, these patients were
exposed to a new cuprophane membrane once every month.
The mean age of the patients was 69 years (range 51 to 76).
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None of the patients had any clinical evidence for an active
inflammatory disease process, malignancy and none were dia-
betic or had IgA nephropathy as the etiology of their chronic
renal failure. None of the patients were on steroid or immuno-
suppressive therapy and none were on aluminum-chelation
therapy with desferrioxamine (which is known to inhibit trans-
ferrin and IL-2 receptors expression) [22].
During the period of the study, there was no statistical change
in the weekly drawn BUN, hematocrit, differential cell counts
or albumin. None of the patients had any evidence of intercur-
rent viral infections, and all were tested to be free from
Hepatitis or HIV infections. Informed consent, approved by the
Vanderbilt University Medical Center and the Nashville VA
Hospital IRB was signed by all participants.
Methods
Study design. The design of the study was a cross over
design. During the first phase of the study all patients were
dialyzed for six consecutive times (3 times a week) with a new
cuprophane hollow fiber membrane (Gambro, GF- 120) (phase
I). After two weeks, the patients were switched to two weeks of
PMMA (TORAY, B2-1.2H) membrane (phase II) and then were
returned to an additional period of new cuprophane membranes
for another period of two weeks (phase III). All other parame-
ters were maintained constant.
Mononuclear cells were harvested from blood drawn pre- and
post-dialysis at the first and sixth (that is, beginning and end of
the two week period) dialysis with each type of membrane.
Control samples, obtained from 18 uremic, non-diabetic and
non-dialyzed patients with serum creatinine greater than 5.0
mg/dl (uremic controls) and from 12 normal volunteers (normal
controls) without known medical problems, were assessed in
parallel.
Peripheral blood mononuclear cell (PBMNC) culture. Thirty
cc of blood were mixed with equal amounts of Hank's balanced
salt solution (HBSS; Gibco, Grand Island, New York, USA)
and carefully layered over Histopaque (Sigma Chemical Co.,
St. Louis, Missouri, USA) media allowing gradient density
centrifugation. The mononuclear cell layer was collected and
washed twice with HBSS and then resuspended in RPMI 1640
supplemented with 2 mrvi L-glutamine (Gibco), 100 U/mI peni-
cillin U, 10 sg/ml Streptomycin (Sigma) and 10% de-comple-
mented, sterile-filtered certified fetal calf serum (FCS; (Gibco).
PBMNC (5 x l0 cells/ml) were placed in 24 well plates
(NUNC) and incubated for four days at 37°C in a 5% CO2
saturated humidity incubator (Forma Scientific). Viability by
Trypan blue dye exclusion was >99% at the beginning of the
culture and >90% at the end of the four-day culture period. Part
of the cultures were activated with 1% vol/vol Phytohemagglu-
tinin (PHA-M, Gibco) in parallel, to investigate the ability of
these cells to express high affinity IL-2R [161.
Cytofluorometric studies. I) IL-2Ra (p55) expression. Cell
pellets (2 x 106 cells) were harvested on the fourth day of
culture and incubated in 500 d phosphate-buffered saline (PBS)
with 2% FCS, 0.1% sodium azide (modified PBS) with 5 d
fluorescein conjugated anti-IL-2Ra antibody (Becton-Dickin-
son) for 30 minutes at 4°C in the dark. Cells were then washed
twice with 2 ml of the modified PBS and kept in 500 pi of this
solution at 4°C until cytometric analysis, generally less than two
hours after staining.
Green fluorescence analysis was performed on a flow cytom-
eter EPICS 753 with Argon Laser. Fluorescence was standard-
ized each day by fluorescent microbeads and voltage, and
amplification and compensation was kept identical for all pro-
cedures. The percentage of IL-2Rcl positive cells and the mean
log fluorescence channel (log units) of positive cells were
analyzed on 5,000 lymphocytes gated by size and granularity
and recorded on a Coulter computer using Immuno" (Diagnos-
tics) software. Background autofluorescence with unstained
cells from the same experiments and non-specific staining of
cells with irrelevant mouse IgG-FITC were digitally subtracted.
2) IL-2Rf3 (p70) expression. Two times 106 cells were simi-
larly incubated with 1 jig anti-IL-2R13 antibody (mouse hybrid-
oma IgG2, supplied by H. Helderman) and revealed with 5 d
fluorescien isothionate conjugated (FITC) goat antimouse
F(ab)'2 fragment (Becton Dickinson). Cytofluorometric analysis
for IL-2R/3 expression was performed using procedures similar
to those described for IL-2Ra expression. IL-2Rf3 expression
was measured only during phase III when the antibody became
available to the authors.
Radioreceptor assay of high affinity IL-2 receptor. Briefly
PHA-induced blasts were counted and incubated for one hour
at 37°C in fresh RPM! 1640 to remove endogenous IL-2 then
resuspended with V25 IL-2 (Dupont NEN, Wilmington, Dela-
ware, USA) in triplicates of 2 x 106 cells in 100 d RPMI 1640
supplemented with 10% FCS in 1.5 ml Eppendorf silanized
(SIGMACOTE) microtest tubes. The method used has been
detailed elsewhere [161. Serial dilutions of 1125 IL-2 were
assayed in this culture to determine the saturation (plateau) of
specific high affinity binding. This was observed at a concen-
tration of IL-2 between 10 and 50 p (data not shown). Further
studies were carried out using 50 M of IL-2. The specific
radioactivity of the probe (1.7 x 10 dpm/pM) was used to
convert maximal levels of bound radioactivity to number of
binding sites per cell, assuming one receptor per bound mole-
cule of IL-2. Control experiments with unstimulated cells or
100-fold excess cold IL-2 confirmed only minor nonspecific
binding (<10% maximal binding of the I'25-IL-2).
Direct effects of dialysis membranes. To investigate the
direct effects of the dialysis membrane, independent of comple-
ment products or cytokines, we prepared small volume dialyz-
ers, made of the same hollow fiber membranes as used clini-
cally, but with a fiber bundle volume of approximately 1.5 to 2.0
ml. Such "minidialyzers" were manufactured from cu-
prophane, PMMA and PAN (polyacrylonitrile) fibers. These
minidialyzers were sterilized before each use with high pressure
steam.
Role of monocytes. To ascertain the role of monocytes in the
in vitro experiments described above, PBMNC from the same
normal controls were further purified by passage through nylon
wool columns and panning to yield mostly T-cells. Purity of the
yield was confirmed by an increase in the CD3 staining of 74.8
3.2% and a loss of monocyte markers (CD 14 staining less
than 0.6% and CD35 less than 1.2%). These purified T-cells
were then incubated in the minidialyzers for four hours and
cultured as described previously at 37°C in 5% CO2 for four
days.
Endotoxin contamination. Supernatants of cultures from in
vitro dialyzer incubation and from the cross over study were
tested by a quantitative LAL assay (LAL, QCL 1000, Whit-
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Fig. 1. Percent of PBMC expressing IL-2Ra (p55) subunit during
chronic dialysis with new cuprophane membrane (phase I). Symbols
are: (U) pre-dialysis, () post-dialysis, (•) uremic and normal controls.
After two weeks, the percent of IL-2Ra positive cells was significantly
higher, both pre- and post-dialysis. **p < 0.005 compared to first
dialysis and controls.
taker Bioproducts Inc., Maryland, USA) and were always
below 2.5 E.U/ml.
Statistical analysis
Comparisons between the different phases of the cross over
study was by the use of multivariate analysis (ANOVA) using
BMDP software package. Statistical significance between dia-
lyzer phases were analyzed using t-test for paired data, whereas
comparison with control groups was done using non-paired
t-test, after testing for normality.
Results
Spontaneous IL-2Rcs expression during dialysis
Prior to beginning the experimental period with new cu-
prophane membranes, the percent IL-2Ra (p55) positive cells in
our study population was 2.6 0.3%, which was not signifi-
cantly different from uremic non-dialyzed or normal controls
(2.7 0.6%; Fig. 1).
Following the first dialysis with new cuprophane membrane,
there was an increase in the number of IL-2Ra positive cells
from 2.6 0.3% to 3.8 0.5% (P = NS). However, when
sampled at the sixth dialysis, the number of IL-2Rs positive
cells had increased to 7.5 2.7% pre-dialysis, and 9.9 1.6%
post-dialysis, both significantly greater (P < 0.005) than con-
trols or values at the beginning of the first phase (Fig. I). During
the first dialysis with the PMMA membrane, the percent of
IL-2Ra positive cells remained significantly high, (10.7 2.5%,
pre-dialysis and 9.4 2.6% post-dialysis). However, prior to
the last (6th) dialysis on PMMA membrane, the number of
IL-2Ra positive cells had returned to baseline value, 3.8 0.8%
(Fig. 2). When the same patients were again dialyzed with new
cuprophane membranes (phase III) results similar to phase I
were obtained. Thus, the percent of cells expressing IL-2Ra
increased from 2.9 0.6% before the first dialysis with cu-
prophane membrane to 8.4 1.6% after the sixth dialysis with
this membrane (P < 0.05 compared to baseline) (Fig. 2).
Density of IL-2Ra expression per cell was assessed by the
mean log fluorescence channel (log units) of IL-2Ra positive
cells. The mean log fluorescence channel (MLFC) was also
increased by the chronic use of new cuprophane from 36.3
2.7 log units at the beginning of the study to 52.3 1.2 log units
after the sixth new cuprophane dialysis during phase I (Table 1).
The MLFC decreased during dialysis with the PMMA mem-
brane (phase II) but increased again during phase III when
cuprophane membrane was again used for a further two week
period (Table 1). Thus, chronic dialysis with new cuprophane
membranes leads to an increase in the percent of IL-2Ra
positive cells and these cells express higher density of IL-2Rcs
on their surfaces. These effects are reversible with the use of
non-cellulosic membranes such as PMMA.
Spontaneous IL-2Rf3 expression during dialysis
IL-2Rf3 is constitutively expressed on cell surfaces of PBMC;
in normal unstimulated controls, 24.9 1.2% of PBMC spon-
taneously express IL-2R/3 on their surfaces (Fig. 3). During
phase III, when new cuprophane membrane was again used, the
percentage of IL-2R13 positive cells increased from 40.8 5.3%
of cells at the beginning of phase III to 58.0 2.3% (P < 0.05
vs. control) just before the sixth dialysis with new cuprophane
membrane and reached 65.4 2.0% post-dialysis (P < 0.05 vs.
pre-dialysis).
The cellular density of IL-2R/3 positive cells, assessed by
MLFC of positive cells, was also increased during dialysis with
cuprophane membranes (phase III) from 41 2.1 log units prior
to the first dialysis to 65 3.1 log units at the end of the sixth
dialysis (P < 0.02 from baseline)
PHA -stimulated high-affinity IL-2 receptors (IL-2R)
The number of cells expressing IL-2Ra as well as IL-2R/3
were significantly and maximally increased in PHA stimulated
PBMC harvested from patients chronically dialyzed with re-
used cuprophane membranes, uremic (non-dialyzed) controls
as well as normal controls. Furthermore, there were no differ-
ences in the percent positive cells or the MLFC of these cells
between these groups. Thus, the percent of positive cells in
these mitogen stimulated cultures was 82.5 7% for IL-2Ra
and greater than 92.7 6.5% for IL-2Rf3 subunits. MLFC was
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Fig. 2. During dialysis with the PMMA membrane, the % of PBMC
expressing IL-2Ra returns to baseline (A), but is again increased during
the third phase of the study using cuprophane membrane (B). Symbols
are: (U) pre-dialysis, () post-dialysis. P < 0.05; ** < 0.005
compared to first dialysis of phase I.
1st dialysis 6th dialysis 1st dialysis 6th dialysis
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Table 1. Mean log fluorescence channel units (MLFC) of IL-2Ra positive cells in unstimulated cultures of PBMC dunng the cross-over study
Phase I
cuprophane
Phase II
PMMA
1st
Dialysis
Phase III
cuprophane
6th
Dialysis
1st
Dialysis
6th
Dialysis
1st
Dialysis
6th
Dialysis
MFLC
SEM
36.3/36.3
2.7/1.5
48.3a/52.3a
1.4/1.2
41.4/38
1.3/0.7
28.2a/28.5a
2.5/1.4
27.5/34.3
3.9/3.6
37.0/43.3a
4.9/3.2
For each dialysis, the values (I) represent pre/post-dialysis MLFC.
a P < 0.05 vs. first dialysis
A Phase I B Phase II
a)
4500
a
a)
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1500 ili 1
Phase Ill
a)csj 80
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Fig. 3 The effect of dialysis with cuprophane membrane (phase III),
on IL-2Rf3 expression. Prior to the first new cuprophane dialysis, the
percent of IL-2R/3 positive cells was 40.8 5.3%. During the sixth
dialysis with cuprophane membrane, the percent of PBMC with IL-2R/3
expression increased from 58.0 2.3% pre-dialysis (La) to 65.4 2.0%
post-dialysis (s). < 0.01 compared to uremic controls (U).
0.01 compared to pre-dialysis.
71.0 7.8 log units for IL-2Ra and 75.2 2.1 log units for
IL-2Rp, respectively.
PBMC harvested pre- and post-dialysis at the beginning and
end of each of the three phases of the study were then assessed
for their capacity to express high-affinity IL-2R receptors. PHA
stimulation induced the expression of high affinity IL-2R in
PBMC harvested from dialysis patients during the three exper-
imental phases, but the extent of this expression varied depend-
ing on sampling time (Fig. 4). Prior to the initiation of the first
cuprophane dialysis (phase I), the number of inducible IL-2R
receptors per cell was 4152 177 receptors/cell, similar to
levels seen in cells obtained from normal and uremic controls
(4174 107 receptors/cell). After the first dialysis with cu-
prophane membrane, the maximal PHA inducible number of
IL-2R expressed was only 2451 200 receptors per cell,
significantly less than pre-dialysis (P < 0.01). After two weeks
of dialysis with the cuprophane membrane, the ability of PHA
to induce high affinity receptors remained significantly attenu-
ated even in pre-dialysis cultures (mean number of receptors
3352 176; P < 0.01). This was further reduced to 2720 267
receptors/cell post-dialysis induced by PHA at the last (6th)
dialysis with cuprophane membrane. Although the mitogen-
induced expression of high affinity IL-2R was still impaired at
the first PMMA dialysis (2768 276 high affinity receptors/cell
pre-dialysis), it improved after two weeks of PMMA dialysis
(3528 142 receptors/cell). Furthermore, there was no signifi-
ctrl 1st dialysis 6th 1st 6th
Fig. 4. The number of high affinity JL-2R on PHA stimulated PBMC
during 2 weeks of cuprophane (phase I) and PMMA (phase II) mem-
brane dialysis. The number of IL-2R decreases post-dialysis ()
compared to predialysis (LI) during the initial dialysis and is further
decreased pre-dialysis during the sixth dialysis of phase I. The findings
are reversed during phase II but recur during phase III. < 0.01
compared to pre-dialysis values of the first cuprophane dialysis (phase
I) and controls (U).
cant difference in PHA induced IL-2R between the pre- and
post-dialysis samples in this phase of the study. The decrease
during the second period of cuprophane exposure (phase III)
was similar to phase I (data not shown). In four patients studied
at the end of a third week of new cuprophane dialysis (phase
III), the number of high affinity receptors post-dialysis induced
by PHA mitogen remained low (2799 321 receptors/cell) but
was not significantly different from its value at the end of two
weeks. Thus recurrent dialysis with new cuprophane membrane
attenuates the ability of lymphocytes to respond to mitogenic
stimulation in terms of expression of high affinity IL-2R; this
effect is reversible by the use of non-cellulosic membranes such
as PMMA.
In vitro incubation of PBMC with dialysis membranes
We incubated PBMC obtained from normal volunteers in
various small volume dialyzers made from different types of
fibers currently in use (cuprophane, polymethylmethacrylate,
polyacrylonitrile) without further stimulation. As can be seen in
Figure 5, whereas incubation with synthetic membrane dialyz-
ers which do not have the polysaccharide structure of the
cuprophane membrane, such as the PMMA or PAN (AN69)
membranes resulted in no significant increase in the percent of
cells expressing IL-2Ra, incubation of the same cells with the
cuprophane hollow fiber membrane in vitro for four hours prior
to culture resulted in a significant increase both in the percent of
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Fig. 5. In vitro incubation of normal PBMC with hollow fiber dialysis
membranes before (U) and after () incubation with C5,. Cuprophane
membrane directly increases the % of PBMC expressing IL-2Ra.
Addition of C5a at 50 ng/ml further increases this percentage, but has no
appreciable effect on PMMA or PAN non-cellulosic membranes. *D <
0.01 compared to control and non-complement activating membranes;
**p < 0.05 compared to unstimulated cells incubated with cuprophane.
those cells (4.9 1.1%, P < 0.01) as well as the density of
receptors as determined by MLFC (from 24.0 5.0 log units to
32.0 7.0 log units, P < 0.05). The addition of the anaphyla-
toxin C5a to the culture media prior to their incubation with this
hollow fiber dialyzer membrane lead to a further increase in the
percent of IL-2Ra positive cells to 8.1 2.5% (P < 0.05);
concomitantly the MLFC increased to 39.0 5.0 log units (P <
0.05 compared to unstimulated cultures).
IL-2R/3 expression was also affected by incubation with the
cuprophane minidialyzer. The percentage of mononuclear cells
expressing IL-2Rj3 was increased by direct contact with the
membrane (from 24.9 1.2% at baseline to 47.3 4.6%) and
was further increased when C5a was added prior to incubation,
to 79,5 4.2% (P < 0.01 vs. baseline). Density of receptors as
assessed by MLFC of positive cells also increased significantly
from 22.0 5.0 to 37.0 8.0 log units after cuprophane
incubation and 49.0 7.0 log units when C, was added to the
culture.
Role of monocytes in in vitro experiments
Incubation of the monocyte-free purified T-cell population
with cuprophane membrane alone or following the addition of
C5a resulted in no increase in IL-2Ra or f expression and no
change in the MLFC. Thus monocyte free cultures of PBMC do
not respond to C5a or to the polysaccharide structure of
cuprophane.
Discussion
The present cross-over study highlights the participation of
lymphocytes in the blood-membrane interactions occurring
during dialysis with cuprophane membrane. Chronic dialysis
with cuprophane membranes, the most widely used dialysis
membrane and one which is associated with activation of
several pathways of the inflammatory response [1—4], leads to
an increase in the expression of IL-2Ra and IL-2R/3 subunits,
markers of lymphocyte activation. More importantly, the num-
ber of high affinity receptors elicited by PHA is significantly
reduced. These findings are seen following as little as two
weeks of dialysis with new cuprophane membrane, and persist
in the patients for at least an interdialytic period, as seen during
the cross over period of 72 hours from the sixth dialysis with
cuprophane to the first dialysis with PMMA. However, com-
parison of the changes of IL-2 receptors at two weeks and at
three weeks of cuprophane membrane exposure suggests that
these defects are not progressive beyond two weeks.
Increased IL-2Ra expression, concomitant with decreased
ability to express high affinity IL-2R by lymphocytes stimulated
with mitogens has been shown in a number of disease states
associated with impaired immune responses [17—21]. Although
these findings appear at first glance discrepant, recent studies
have suggested that T-lymphocytes that have undergone a cycle
of proliferative response become refractory to further stimula-
tion by various mitogens and antigens, and have decreased
IL-2R response upon successive stimulation [23, 24]. Thus our
hypothesis is that the extent of IL-2Ra and p subunits ex-
pressed on lymphocytes harvested following chronic dialysis
with cuprophane membrane is an index of their pre-activation
and may make them refractory to subsequent mitogenic stimu-
lation by limiting their expression of high affinity IL-2R.
The presence of high affinity IL-2R is crucial for T-cell
activation and differentiation since it is a target of the T-cell
growth factor IL-2 [9, 12, 24, 25]. In association with low
bioavailability of IL-2 in supernatants of stimulated uremic
T-cells [7, 26, 27], the present study may shed some light on
various observations of defective cell-mediated immune re-
sponse in hemodialysis patients. These include decreased pro-
liferation and low IL-2 production in response to antigenic and
mitogenic challenge [7, 27], cutaneous anergy [28, 29], de-
creased antibody response to T-helper dependent antigen proc-
essing such as influenza [30] and hepatitis B vaccine [31],
increased incidence of cell-mediated infections such as myco-
bacterium tuberculosis [32, 33] or viral hepatitis B [34].
Several observations made in this and other studies suggest
that the primary defect in the attenuated lymphocyte responses
seen in hemodialysis patients may reside in the monocytes.
Meuer and colleagues have suggested that the decreased pro-
liferative response of T-lymphocytes in hemodialysis patients is
due to defective monocyte activation and in particular their
inability to support primary T-cell activation in vitro; when the
activation pathway of lymphocyte bypasses monocyte stimula-
tion the T lymphocyte response returns to normal [35]. Tsako-
los et a! have also shown that the lymphocyte proliferative
response is impaired in hemodialysis patients but is corrected
by addition of control monocytes [36]. Recent studies on
monocyte activation during dialysis with cuprophane mem-
branes [21 as well as our own observations in this study have
pointed out that monocyte activation can occur even in the
absence of complement activation, by direct interaction of the
monocytes with the polysaccharide structure of the cupróphane
membrane [2, 37].
Thus, our hypothesis is that the immunomodulatory effects of
the cuprophane membrane are mediated by the chronic stimu-
lation of monocytes either by direct contact with the polysac-
chande structure of cuprophane or via their C5a receptors
leading to a persistent up-regulation of IL-2Ra and f3subunits
on lymphocytes. This chronic stimulation decreases the re-
sponse to further antigenic or mitogenic stimuli [23, 24]. This is
also supported by our observation on the reversibility of these
findings when a non-cellulosic (and non-complement activating)
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dialysis membrane is utilized. This hypothesis needs to be
confirmed by further studies.
While these indices of lymphocyte activation were not
present when the study was initiated in patients chronically
dialyzed with formaldehyde-reused dialyzers (which have a
markedly attenuated complement activation capacity), it is
important to point out that chronic dialysis with cuprophane
dialyzers reused with bleach (which leads to recurrent comple-
ment activation [381 and is prevalent in greater than 30% of
dialysis units) may well result in similar findings.
Finally, although these findings of reduced inducible IL-2
receptors are seen as early as two weeks after initiation of new
cuprophane dialysis, and persist for up to three weeks, longer
term studies are needed to define the persistence of these
findings during chronic hemodialysis as well as to define the
time course of the onset of reduced IL-2 receptor expression
pre-dialysis.
In summary, dialysis with cuprophane membranes leads to a
low grade stimulation of lymphocytes as expressed by in-
creased IL-2Ra and f3 subunits but impairs their expression of
high affinity IL-2R, while dialysis with non-cellulosic activating
membranes reverses many of these abnormalities. While it is
difficult to extrapolate these findings to clinical observations of
immune deficiency in dialysis patients, the present cross-over
study highlights the potential deleterious role of cellulosic
membranes on the immune response of chronic hemodialysis
patients. A potential pathogenesis of these defects may be in the
chronic activation of complement and monocytes by these
membranes.
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